...
首页> 外文期刊>BMC Cancer >Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer
【24h】

Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer

机译:从固体癌患者的血浆中肿瘤衍生细胞外囊泡的检测

获取原文
           

摘要

Extracellular vesicles (EVs) are actively secreted by cells into body fluids and contain nucleic acids of the cells they originate from. The goal of this study was to detect circulating tumor-derived EVs (ctEVs) by mutant mRNA transcripts (EV-RNA) in plasma of patients with solid cancers and compare the occurrence of ctEVs with circulating tumor DNA (ctDNA) in cell-free DNA (cfDNA). For this purpose, blood from 20 patients and 15 healthy blood donors (HBDs) was collected in different preservation tubes (EDTA, BCT, CellSave) and processed into plasma within 24?h from venipuncture. EVs were isolated with the ExoEasy protocol from this plasma and from conditioned medium of 6 cancer cell lines and characterized according to MISEV2018-guidelines. RNA from EVs was isolated with the ExoRNeasy protocol and evaluated for transcript expression levels of 96 genes by RT-qPCR and genotyped by digital PCR. Our workflow applied on cell lines revealed a high concordance between cellular mRNA and EV-RNA in expression levels as well as variant allele frequencies for PIK3CA, KRAS and BRAF. Plasma CD9-positive EV and GAPDH EV-RNA levels were significantly different between the preservation tubes. The workflow detected only ctEVs with mutant transcripts in plasma of patients with high amounts (?20%) of circulating tumor DNA (ctDNA). Expression profiling showed that the EVs from patients resemble healthy donors more than tumor cell lines supporting that most EVs are derived from healthy tissue. We provide a workflow for ctEV detection by spin column-based generic isolation of EVs and PCR-based measurement of gene expression and mutant transcripts in EV-RNA derived from cancer patients’ blood plasma. This workflow, however, detected tumor-specific mutations in blood less often in EV-RNA than in cfDNA.
机译:细胞外囊泡(EVS)被细胞与体液中的体液一起分泌并含有它们源自它们的细胞的核酸。本研究的目的是通过固体癌症患者的血浆中突变体mRNA转录物(EV-RNA)检测循环肿瘤衍生的EV(CTEV),并将CTEV的发生与无细胞DNA中的循环肿瘤DNA(CTDNA)进行比较(CFDNA)。为此目的,在不同的保存管(EDTA,BCT,Cellave)中收集来自20名患者和15名健康血液供体(HBD)的血液,并在静脉穿刺中加工成24μm的血浆。从该等离子体和6种癌细胞系的调节培养基中与eVeeasy方案分离EV,并根据MISEV2018-指导来表征。来自EVS的RNA与EVERNEASY方案分离,并通过RT-QPCR评估了96个基因的转录表达水平,并通过数字PCR进行基因分型。我们在细胞系上应用的工作流程表达表达水平中的细胞mRNA和EV-RNA之间的高一致性,以及PIK3CA,KRAS和BRAF的变异等位基因频率。在保存管之间血浆CD9阳性EV和GAPDH EV-RNA水平显着差异。工作流程仅检测到具有大量(& 20%)循环肿瘤DNA(CTDNA)血浆血浆中的突变体转录物的CTEV。表达分析表明,来自患者的EVS类似于肿瘤细胞系,支持大多数EVS来自健康组织的肿瘤细胞系。我们为CTEV检测通过旋转柱的通用隔离来提供CTEV检测的工作流程,并基于PCR的基因表达和突变体转录物中来自癌症患者血浆的EV-RNA中的突变转录物。然而,这种工作流程在EV-RNA中较少地检测到血液中的肿瘤特异性突变而不是CFDNA。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号